Times:

01:33 Cyllene Tx

21:37 LinusBio

This week, we have conversations with LinusBio founder and Mt. Sinai environmental professor, Dr. Manish Arora, as well as with Philippe Chambon, CEO of Cyllene Therapeutics (Cyllene Tx).

Cyllene Therapeutics

Cyllene Therapeutics is a global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology. It is currently executing a phase 1/2 study in the US with its lead DNA medicine candidate, EG110A, in patients with neurogenic detrusor overactivity (neurogenic bladder)-related incontinence.

This is the first human study with nrHSV vectors targeting sensory neuron-based diseases. EG110A is being developed to address multiple severe bladder diseases, including overacti ...